CA2086974A1 - R(+)-terazosin - Google Patents
R(+)-terazosinInfo
- Publication number
- CA2086974A1 CA2086974A1 CA002086974A CA2086974A CA2086974A1 CA 2086974 A1 CA2086974 A1 CA 2086974A1 CA 002086974 A CA002086974 A CA 002086974A CA 2086974 A CA2086974 A CA 2086974A CA 2086974 A1 CA2086974 A1 CA 2086974A1
- Authority
- CA
- Canada
- Prior art keywords
- terazosin
- hydratet
- furanyl
- enantiomer
- piperazinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine hydrochloride or a pharmaceutically acceptable salt or hydratet thereof, substantially free of the S(-)-enantiomer.
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/546,349 US5212176A (en) | 1990-06-29 | 1990-06-29 | R(+)-terazosin |
IE208691A IE72967B1 (en) | 1990-06-29 | 1991-06-18 | R(+)-Terazosin |
IL9856291A IL98562A (en) | 1990-06-29 | 1991-06-19 | R(+)-2- [4-[(tetrahydro-2-furanyl) carbonyl]-1-piperazinyl] 6-7-dimethoxy-4-quinazolinamine and pharmaceutical compositions containing it |
AT91914562T ATE136779T1 (en) | 1990-06-29 | 1991-06-26 | R(+)-TERAZOSINE |
PCT/US1991/004562 WO1992000073A1 (en) | 1990-06-29 | 1991-06-26 | R(+)-terazosin |
JP3513458A JPH07119222B2 (en) | 1990-06-29 | 1991-06-26 | R (+)-terazosin |
AU83231/91A AU654148B2 (en) | 1990-06-29 | 1991-06-26 | R(+)-terazosin |
EP91914562A EP0536329B1 (en) | 1990-06-29 | 1991-06-26 | R(+)-terazosin |
DE69118889T DE69118889T2 (en) | 1990-06-29 | 1991-06-26 | R (+) - TERAZOSIN |
DK91914562.3T DK0536329T3 (en) | 1990-06-29 | 1991-06-26 | R (+) - terazosin |
ES91914562T ES2089224T3 (en) | 1990-06-29 | 1991-06-26 | R (+) - TERAZOSIN. |
PT98148A PT98148B (en) | 1990-06-29 | 1991-06-28 | PREPARATION PROCESS FOR R (+) - 2- {4 - {(TETRAHYDRO-2-FURANYL) CARBONYL} -1-PYRAZAZYL} -6,7-DIMETHOXY-4-QUINAZOLINAMINE AND THEIR PHARMACEUTICALLY ACCEPTANT, SUBSTANTIALLY, OF ENANTIOMERO S (-) AND OF PHARMACEUTICAL COMPOSITIONS |
CA002086974A CA2086974C (en) | 1990-06-29 | 1993-01-08 | R(+)-terazosin |
GR960401733T GR3020364T3 (en) | 1990-06-29 | 1996-06-27 | R(+)-terazosin |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/546,349 US5212176A (en) | 1990-06-29 | 1990-06-29 | R(+)-terazosin |
PCT/US1991/004562 WO1992000073A1 (en) | 1990-06-29 | 1991-06-26 | R(+)-terazosin |
CA002086974A CA2086974C (en) | 1990-06-29 | 1993-01-08 | R(+)-terazosin |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2086974A1 true CA2086974A1 (en) | 1994-07-09 |
CA2086974C CA2086974C (en) | 2001-04-10 |
Family
ID=25675811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002086974A Expired - Fee Related CA2086974C (en) | 1990-06-29 | 1993-01-08 | R(+)-terazosin |
Country Status (14)
Country | Link |
---|---|
US (1) | US5212176A (en) |
EP (1) | EP0536329B1 (en) |
JP (1) | JPH07119222B2 (en) |
AT (1) | ATE136779T1 (en) |
AU (1) | AU654148B2 (en) |
CA (1) | CA2086974C (en) |
DE (1) | DE69118889T2 (en) |
DK (1) | DK0536329T3 (en) |
ES (1) | ES2089224T3 (en) |
GR (1) | GR3020364T3 (en) |
IE (1) | IE72967B1 (en) |
IL (1) | IL98562A (en) |
PT (1) | PT98148B (en) |
WO (1) | WO1992000073A1 (en) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL101243A (en) * | 1991-03-20 | 1999-12-22 | Merck & Co Inc | Pharmaceutical compositions for treatment of benign prostatic hyperplasia comprising a steroid derivative |
NZ257993A (en) * | 1992-11-04 | 1997-05-26 | Sepracor Inc | Use of (+)-doxazosin and medicament containing the compound |
AU5549494A (en) * | 1992-11-04 | 1994-05-24 | Sepracor, Inc. | Methods and compositions of (+) doxazosin for the treatment of hypertension |
US5294615A (en) * | 1993-04-29 | 1994-03-15 | Abbott Laboratories | Terazosin polymorph and pharmaceutical composition |
US5412095A (en) * | 1993-04-29 | 1995-05-02 | Abbott Laboratories | Terazosin monohydrochloride and processes and intermediate for its production |
US5504207A (en) * | 1994-10-18 | 1996-04-02 | Abbott Laboratories | Process and intermediate for the preparation of terazosin hydrochloride dihydrate |
US5587377A (en) * | 1995-10-24 | 1996-12-24 | Invamed, Inc. | Terazosin crystalline polymorph and pharmaceutical compositions thereof |
JPH11507395A (en) * | 1995-11-15 | 1999-06-29 | メルク エンド カンパニー インコーポレーテッド | Alpha 1a adrenergic receptor antagonist |
DE19546573A1 (en) * | 1995-12-13 | 1997-06-19 | Uetikon Chemie Gmbh | Crystalline polymorph of terazosin hydrochloride, and process for its preparation |
US5952003A (en) * | 1996-08-01 | 1999-09-14 | Novartis Corporation | Terazosin capsules |
US5922722A (en) * | 1996-11-12 | 1999-07-13 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
IT1286789B1 (en) * | 1996-11-29 | 1998-07-17 | Alfa Chem Ital | PROCESS FOR THE PRODUCTION OF FORM I OF ANHYDROUS MONOCLORIDATE TERAZOSIN |
GB9708917D0 (en) * | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
US6214832B1 (en) | 1997-06-18 | 2001-04-10 | Merck & Co., Inc. | Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists |
US6376503B1 (en) | 1997-06-18 | 2002-04-23 | Merck & Co., Inc | Alpha 1a adrenergic receptor antagonists |
US6080760A (en) * | 1997-06-18 | 2000-06-27 | Merck & Co., Inc. | Alpha 1A adrenergic receptor antagonists |
US6143750A (en) * | 1997-06-18 | 2000-11-07 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6057350A (en) * | 1997-06-18 | 2000-05-02 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6037354A (en) | 1997-06-18 | 2000-03-14 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6248888B1 (en) | 1997-11-14 | 2001-06-19 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of terazosin hydrochloride dihydrate |
AU5234899A (en) | 1998-07-30 | 2000-02-21 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
AU1808400A (en) | 1998-10-29 | 2000-05-22 | Merck & Co., Inc. | Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists |
US6319932B1 (en) | 1998-11-10 | 2001-11-20 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1A adrenoceptor antagonists |
US6228870B1 (en) | 1998-11-10 | 2001-05-08 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1a adrenoceptor antagonists |
AU1345600A (en) | 1998-11-12 | 2000-06-05 | Merck & Co., Inc. | Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists |
DE19861323B4 (en) * | 1998-12-08 | 2006-02-16 | Robert Bosch Gmbh | Method for transmitting short messages |
DE19856440C2 (en) * | 1998-12-08 | 2002-04-04 | Bosch Gmbh Robert | Transmission frame and radio unit with transmission frame |
US6358959B1 (en) | 1999-01-26 | 2002-03-19 | Merck & Co., Inc. | Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355456A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355263A (en) | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355457A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355264A (en) | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
US6200573B1 (en) | 1999-12-03 | 2001-03-13 | Starcor Pharmaceuticals, Inc. | Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia |
US7335803B2 (en) | 2001-10-19 | 2008-02-26 | Allergan, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
US6313172B1 (en) | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
JP2002121188A (en) * | 2000-07-18 | 2002-04-23 | Toray Ind Inc | Method for manufacturing piperazine amide compound and piperazine-tetrahydrofuran-2-carboxylic acid amide derivative |
US20020198215A1 (en) * | 2000-10-23 | 2002-12-26 | Lino Tavares | Terazosin transdermal device and methods |
US6534542B2 (en) | 2001-02-27 | 2003-03-18 | Allergen Sales, Inc. | (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors |
KR20040088519A (en) | 2002-02-22 | 2004-10-16 | 뉴 리버 파마슈티칼스, 인크. | Active Agent Delivery Systems and Methods for Protecting and Administering Active Agents |
US7358269B2 (en) | 2002-05-21 | 2008-04-15 | Allergan, Inc. | 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one |
US7276522B2 (en) | 2002-05-21 | 2007-10-02 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7323485B2 (en) | 2002-05-21 | 2008-01-29 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
EP2335734A3 (en) | 2003-09-12 | 2012-01-11 | Allergan, Inc. | Treatment of pain and other alpha 2 adrenergic-mediated conditions |
US7390829B2 (en) | 2005-06-29 | 2008-06-24 | Allergan, Inc. | Alpha-2 adrenergic agonists |
US7323477B2 (en) | 2006-02-02 | 2008-01-29 | Allergan, Inc. | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline |
AU2007286186A1 (en) * | 2006-08-08 | 2008-02-21 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects |
US7598417B2 (en) | 2007-04-12 | 2009-10-06 | Allergan, Inc. | Substituted fluoroethyl ureas as alpha 2 adrenergic agents |
AU2008254717B2 (en) | 2007-05-23 | 2014-06-05 | Allergan, Inc. | Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure |
CA2687976C (en) | 2007-05-23 | 2015-04-07 | Allergan, Inc. | Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds |
US7902247B2 (en) | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
US7829587B2 (en) | 2008-01-09 | 2010-11-09 | Allergan, Inc. | Substituted 2-aminotetralin derivatives as selective alpha 2B agonist |
US8809379B2 (en) | 2008-01-18 | 2014-08-19 | Allergan, Inc. | Selective subtype alpha 2 adrenergic agents and methods for use thereof |
US8362022B2 (en) | 2008-01-18 | 2013-01-29 | Allergan, Inc. | Selective subtype alpha 2 adrenergic agents and methods for use thereof |
US20090239918A1 (en) * | 2008-03-24 | 2009-09-24 | Allergan, Inc. | Selective subtype alpha 2 adrenergic agents and methods for use thereof |
US8420114B2 (en) | 2008-04-18 | 2013-04-16 | Warsaw Orthopedic, Inc. | Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation |
US9072727B2 (en) | 2008-04-18 | 2015-07-07 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
EP2280707A1 (en) | 2008-05-05 | 2011-02-09 | Allergan, Inc. | Alpha2b and alpha2c agonists |
AU2009246572A1 (en) | 2008-05-16 | 2009-11-19 | Allergan, Inc. | Selective subtype alpha 2 adrenergic agents and methods for use thereof |
AU2009333620A1 (en) | 2008-12-08 | 2011-07-07 | Allergan, Inc. | N-(1-phenyl-2-arylethyl)-4,5-dihydro-3H-pyrrol-2-amine compounds as subtype selective modulators of alpha2B or alpha2B and alpha2C adrenoceptors |
US20110306635A1 (en) | 2009-02-06 | 2011-12-15 | Allergan ,Inc. | Pyridine compounds as subtype selective modulators of alpha2b and /or alpha 2c adrenergic receptors |
EP2459542B1 (en) | 2009-07-30 | 2014-10-29 | Allergan, Inc. | Substituted N-benzyl-4,5-dihydrooxazol-2-amines useful as selective alpha 2B/2C receptor agonists |
EP2486009B1 (en) | 2009-10-06 | 2019-08-21 | Allergan, Inc. | 2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators |
US20160361380A1 (en) | 2015-06-12 | 2016-12-15 | Nymox Corporation | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
US11224572B1 (en) * | 2020-08-17 | 2022-01-18 | Novitium Pharma LLC | Stable oral liquid composition of terazosin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4026894A (en) * | 1975-10-14 | 1977-05-31 | Abbott Laboratories | Antihypertensive agents |
GB1591490A (en) * | 1977-08-04 | 1981-06-24 | Abbott Lab | 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate |
JPH01216983A (en) * | 1988-02-26 | 1989-08-30 | Hiroyuki Nohira | Method for optical resolution of (+-)-tetrahydrofuran-2-carboxylic acid |
-
1990
- 1990-06-29 US US07/546,349 patent/US5212176A/en not_active Expired - Fee Related
-
1991
- 1991-06-18 IE IE208691A patent/IE72967B1/en not_active IP Right Cessation
- 1991-06-19 IL IL9856291A patent/IL98562A/en not_active IP Right Cessation
- 1991-06-26 AU AU83231/91A patent/AU654148B2/en not_active Ceased
- 1991-06-26 EP EP91914562A patent/EP0536329B1/en not_active Expired - Lifetime
- 1991-06-26 JP JP3513458A patent/JPH07119222B2/en not_active Expired - Fee Related
- 1991-06-26 WO PCT/US1991/004562 patent/WO1992000073A1/en active IP Right Grant
- 1991-06-26 AT AT91914562T patent/ATE136779T1/en not_active IP Right Cessation
- 1991-06-26 DE DE69118889T patent/DE69118889T2/en not_active Expired - Fee Related
- 1991-06-26 DK DK91914562.3T patent/DK0536329T3/en active
- 1991-06-26 ES ES91914562T patent/ES2089224T3/en not_active Expired - Lifetime
- 1991-06-28 PT PT98148A patent/PT98148B/en not_active IP Right Cessation
-
1993
- 1993-01-08 CA CA002086974A patent/CA2086974C/en not_active Expired - Fee Related
-
1996
- 1996-06-27 GR GR960401733T patent/GR3020364T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
ATE136779T1 (en) | 1996-05-15 |
WO1992000073A1 (en) | 1992-01-09 |
AU8323191A (en) | 1992-01-23 |
ES2089224T3 (en) | 1996-10-01 |
EP0536329A1 (en) | 1993-04-14 |
GR3020364T3 (en) | 1996-09-30 |
DK0536329T3 (en) | 1996-08-12 |
DE69118889T2 (en) | 1996-11-07 |
PT98148A (en) | 1993-08-31 |
EP0536329A4 (en) | 1993-05-19 |
CA2086974C (en) | 2001-04-10 |
JPH07119222B2 (en) | 1995-12-20 |
US5212176A (en) | 1993-05-18 |
JPH05507280A (en) | 1993-10-21 |
AU654148B2 (en) | 1994-10-27 |
DE69118889D1 (en) | 1996-05-23 |
PT98148B (en) | 1998-12-31 |
EP0536329B1 (en) | 1996-04-17 |
IL98562A (en) | 1995-12-31 |
IE912086A1 (en) | 1992-01-01 |
IE72967B1 (en) | 1997-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2086974A1 (en) | R(+)-terazosin | |
LU88842I2 (en) | Nebivolol optionally in the form of a pharmaceutically acceptable salt or hydrate, in particular Nebivolol hydrochloride | |
AU6798790A (en) | Teat cup inflation | |
AU6062590A (en) | Pharmaceutically active compounds | |
CA2163003A1 (en) | Solubilizer and external preparations containing the same | |
USD398466S (en) | Toilet tissue roll holder | |
CA2143263A1 (en) | Orally administrable raloxifene formulations | |
USD340523S (en) | Orthodontic bracket base | |
ZA9110018B (en) | 2-acylamido derivatives of 3,4-dihydro-3-oxo-quinoxaline having pharmaceutical activity. | |
CA2064373A1 (en) | Piperidine derivatives | |
GR3018031T3 (en) | Apparatus for surgically profiling the cornea using vacuum. | |
CA2027814A1 (en) | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds | |
AU674379B2 (en) | Antitussive | |
USD328845S (en) | Retaining ring mounting clamp | |
USD323043S (en) | Ear protector | |
USD313065S (en) | Faucet set | |
CA2260863A1 (en) | Treatment of psychotic disorders | |
CA2042936A1 (en) | Treatment of ocular hypertension with a synergistic combination for ophthalmic use | |
CA2388830A1 (en) | Oral solution containing galanthamine and a sweetening agent | |
USD320068S (en) | Pedestal lavatory | |
USD332531S (en) | Chair | |
USD324386S (en) | Combined earphones and earmuffs | |
CA2094457A1 (en) | Monoquaternary 2,16-bispiperidinylandrostane derivatives | |
MX9702506A (en) | Sabeluzole oral suspensions. | |
CA2048245A1 (en) | Treatment of cataract with prostacyclin compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |